Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2023-04-04 Board/Management Inform…
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment or dismissal of an outside director (사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고). This falls under the category of board and management changes.
2023-04-04 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, director appointments, and remuneration limits. This aligns perfectly with the definition of a Declaration of Voting Results (DVA).
2023-03-29 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Eubiologics. It provides a summary of the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and details regarding the auditor. While it contains financial data, it is a standard regulatory disclosure announcement in the Korean market (DART system) confirming the receipt and submission of the audit report, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing. FY 2022
2023-03-21 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) for the fiscal year 2022 (Jan 1, 2022 - Dec 31, 2022) for EuBiologics Co., Ltd. It contains comprehensive sections including company overview, business description, financial statements, management discussion and analysis, and auditor's opinion. This structure corresponds to the standard Korean Annual Report (10-K equivalent). FY 2022
2023-03-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (disposal of shares) by an executive (Oh Myung Seok) of Eubiologics. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2023-03-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by a director (CEO) of Eubiologics. This type of filing, which details personal share transactions by company insiders, is classified as a Director's Dealing report.
2023-03-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.